The pharmaceutical company AstraZeneca has offered about $10 billion for the American company Katsav Pharmaceuticals, which specializes in the treatment of rare forms of obesity, Reuters reports. The initial public offering requires a payment of up to $134 per share, subject to additional payments upon the achievement of certain results. It is expected that the deal may go through Alexion's orphan disease division. Following the news, Katsav shares rose by 28%, and the company's market value reached 7.64 billion dollars.